HCRN GU15-215: A phase II trial of atezolizumab (atezo) and bevacizumab (bev) in cisplatin-ineligible patients (pts) with advanced/unresectable urothelial cancer (UC) Meeting Abstract
| Authors: | Balar, A. V.; Funt, S. A.; Gupta, S.; Dudek, A. Z.; Boiles, A. R.; Vaena, D. A.; Kilari, D.; Rosenberg, J. E. |
| Abstract Title: | HCRN GU15-215: A phase II trial of atezolizumab (atezo) and bevacizumab (bev) in cisplatin-ineligible patients (pts) with advanced/unresectable urothelial cancer (UC) |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Language: | English |
| ACCESSION: | WOS:000560368309154 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.TPS5098 |
| Notes: | Meeting Abstract: TPS5098 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
